focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics

6 Feb 2013 16:43

RNS Number : 3023X
D.A.A.Phillips
06 February 2013
 



 FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

D.A.A.Phillips/K.F.Phillips Aquaglow ltd

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Ark Therapeutics

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

06/02'2013

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

YES/NO

If YES, specify which:

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary 1p

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

8,000,000

3.822

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

TOTAL:

8,000,000

3.822

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary 1p

 

 

Purchase

purchase

2,000,000

1.0

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

none

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

none

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES/NO

 

 

 

06/02/13

Contact name:

D.A.A.Phillips

Telephone number:

07775141617

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETUNSNRORAURAR
Date   Source Headline
2nd Jun 20154:55 pmRNSChange of Auditor
29th May 20157:00 amRNSHalf Yearly Report
7th May 20153:42 pmRNSChange of Registered Office
29th Apr 20157:01 amRNSTrading Statement
29th Apr 20157:00 amRNSFinal Results
13th Mar 201511:22 amRNSHolding(s) in Company
9th Mar 20157:00 amRNSRenamed Premier Veterinary Group
3rd Mar 201512:33 pmRNSHolding(s) in Company
3rd Mar 20159:48 amRNSHolding(s) in Company
2nd Mar 20152:36 pmRNSHolding(s) in Company
2nd Mar 201510:55 amRNSHolding(s) in Company
2nd Mar 201510:42 amRNSHolding(s) in Company
27th Feb 20154:35 pmRNSPrice Monitoring Extension
27th Feb 20154:07 pmRNSBoard Changes and Directors' Dealings
27th Feb 20158:00 amRNSCancellation
27th Feb 20157:00 amRNSAdmission to the Official List
26th Feb 20154:00 pmRNSCancellation and Publication of Prospectus
5th Feb 20154:22 pmRNSAcquisition completed
28th Jan 20159:29 amRNSSale and Purchase Agreement Signed
15th Jan 20157:00 amRNSTransfer of listing category on the Official List
4th Dec 201411:17 amRNSBlocklisting Interim Review
21st Nov 20145:48 pmRNSPosting of Circular
1st Aug 20147:00 amRNSHalf Yearly Report and Change of Registered Office
1st Jul 20147:00 amRNSResults of AGM and Board Changes
3rd Jun 20147:00 amRNSBlocklisting Interim Review
13th May 20147:00 amRNSInterim Management Statement
30th Apr 20147:00 amRNSFinal Results
28th Mar 20147:45 amRNSSuspension - Ark Therapeutics Group Plc
28th Mar 20147:32 amRNSSigned Heads of Terms and Suspension of Trading
25th Mar 201412:48 pmRNSHolding(s) in Company
4th Mar 201412:22 pmRNSHolding(s) in Company
21st Feb 20144:40 pmRNSSecond Price Monitoring Extn
21st Feb 20144:35 pmRNSPrice Monitoring Extension
20th Feb 201410:44 amRNSHolding(s) in Company
20th Feb 201410:39 amRNSHolding(s) in Company
20th Feb 201410:38 amRNSHolding(s) in Company
6th Dec 20135:46 pmRNSBlocklisting Interim Review
6th Nov 20137:00 amRNSInterim Management Statement
8th Oct 201311:27 amRNSHolding(s) in Company
7th Oct 20134:35 pmRNSPrice Monitoring Extension
7th Oct 20133:21 pmRNSHolding(s) in Company
27th Sep 201311:46 amRNSHolding(s) in Company
26th Sep 20133:26 pmRNSHolding(s) in Company
24th Sep 201311:02 amRNSHolding(s) in Company
20th Sep 201311:47 amRNSHolding(s) in Company
18th Sep 20134:40 pmRNSSecond Price Monitoring Extn
18th Sep 20134:35 pmRNSPrice Monitoring Extension
17th Sep 201310:00 amRNSHolding(s) in Company
13th Sep 201311:40 amRNSHolding(s) in Company
10th Sep 201310:37 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.